论文部分内容阅读
去年,笔者将一年一度的国内新药综述改为跨年度的年度综述,从而有条件将未能及早介绍的鉴定药物在下一年度介绍,减少了遗漏,收到了预计的效果。本年度介绍的新药共43种,其中属创制性的药物计17种,仿制的药物有20种。这一年度通过临床鉴定的新药中有不少是复方制剂,本文仅有选择地介绍了6种。此外,由不同药厂重复研制并进行临床鉴定的品种。本文不重复报道,也不计入新品种数中。
Last year, the author changed the annual domestic drug reviews to cross-year annual reviews, so as to conditionally submit the appraisal drugs that could not be introduced earlier in the next year, reducing omissions and receiving the expected results. This year introduced a total of 43 kinds of new drugs, of which there are 17 kinds of generative drugs, generic drugs have 20 kinds. Many of the new drugs that have been clinically identified in the past year are in combination, and this article has introduced only six of these. In addition, by different pharmaceutical companies repeatedly developed and clinical identification of varieties. This article does not repeat the report, nor included in the new varieties.